Transcranial direct current stimulation (tDCS) has shown the potential to improve symptoms in patients with movement deficits, such as Parkinson's disease and chronic stroke. However, the effects of tDCS have so far not been proven on a wider scale due to lack of knowledge regarding exactly how tDCS works. This has limited the adoption of this potentially useful therapy for patients with Parkinson's disease, chronic stroke and other conditions affecting movement. We think that by studying the effect of tDCS on brain signals while subjects perform a virtual reality task that requires integration of visual and motor information we can separate out exactly what occurs in the brain when tDCS is turned on. We expect this approach to broaden our understanding of tDCS application in conditions affecting movement and possibly lead to therapeutic advances in this population.
This registry is designed for patients with Parkinson's Disease (PD) who are being considered for treatment with deep brain stimulation (DBS). A registry is a type of observational study that collects information about patients' medical conditions and/or treatments to better understand how a condition or treatment affects patients in the real world.The purpose of the research is to create a list of patients with Parkinson Disease who are all receiving DBS to learn more about the effects of DBS on their PD symptoms
IPX203 is an investigational extended-release (i.e. releases drug more slowly) capsule formulation of carbidopa-levodopa (CD-LD) administered orally (by mouth). "Investigational" means that IPX203 is being tested and has not been approved for marketing.
IPX203 is being investigated to determine whether the drug is safe and potentially has a better effect than currently approved IR CD-LD. If successful, the drug could possibly improve the daily control of motor symptoms in people with Parkinson's disease.
IPX203 is provided as a capsule containing 140 mg LD and 35 mg CD. The study doctor may adjust the IPX203 dosing regimen based on your response to the study drug during the 4 week dose conversion period. Your study doctor will instruct you on the dose of IPX203 or IPX203 placebo that you will receive during the 13-week portion of the study.
Your total participation time in the study will be approximately 24 weeks (6 months), which includes 4 weeks for your initial assessment (screening) period to determine if the trial is suitable for you.
Study I7S-MC-HBEH (HBEH) is a multicenter, randomized (i.e. study in which people are assigned at random (by chance alone) to receive one of several clinical interventions), double-blind (i.e., neither the participant nor the person evaluating for the study knows what group the participant has been assigned to), parallel-group (i.e., a type of study where two groups of treatments, A and B, are given so that one group receives only A while another group receives only B.), placebo-controlled (i.e. one group will receive the study drug and the other will receive a substance that has no therapeutic effect, also known as placebo), fixed-dosage (i.e., the dosage will not change during the course of the study), Phase 2a study (i.e., a trial with the objective of assessing what dose is more effective in treating symptoms.) comparing various dosages of LY3154207 administered orally once a day with placebo over 12 weeks in subjects with mild-to-moderate Parkinson disease dementia (PDD).
The study includes a Screening Period (Visits 1 to 2) of a minimum of 7 days and up to 14 days, a 14-day Pretreatment Period (Visits 2 to 3), a 12-week Treatment Period (Visits 3 to 11), and a 14-day Safety Follow-Up Period (Visit 12).
Your participation will last about 17-18 weeks.
The purpose of this study is to find out how LY3154207 compares with placebo in treating memory and thinking problems in individuals with mild-to-moderate Parkinson's disease dementia.
Candidates for this study may or may not report disturbances in odor perception as their primary reason for seeking treatment at MUSC. This study is designed to collect long term, observational data from patients who are being treated with routine clinical care in health clinics at MUSC. Data from clinical questionnaires will be de-identified and stored in a database.
Transcranial direct current stimulation (tDCS) has shown the potential to improve symptoms in patients with motor deficits, however its effects have not been consistent in randomized studies to date, limiting widespread adoption of this technology. A critical gap in our knowledge is a detailed understanding of how tDCS affects motor areas in the brain. We propose using tDCS while recording directly from motor cortex using subdural electrocorticography (sECoG) in patients undergoing deep brain stimulation surgery. We expect this novel approach to broaden our understanding of tDCS application and possibly lead to therapeutic advances in this population.
The purpose of this study is to evaluate the safety of BIIB054 at several different doses. This study will also look at how BIIB054 affects your body (Pharmacodynamics) and how your body affects BIIB054 (Pharmacokinetics). It will also investigate how your immune system responds to BIIB054.
BIIB054 is an investigational product under development for the treatment of Parkinson's Disease. BIIB054 is an antibody, similar to proteins your body makes to try to rid itself of bacteria, viruses and certain other harmful agents. It is believed to work by attaching to molecules in your brain associated with Parkinson's Disease, called alpha-synuclein, and preventing them from causing damage.
To see how well the study drug works, it will be compared to a placebo in the study. A placebo is just like the study drug but it does not have any active ingredient. This is the best way for testing a new medicine in a research study because it keeps the study results from being influenced by what the research team thinks or hopes the new medicine might do.
BIIB054 or placebo will be administered by trained staff at the study center as an intravenous (IV) infusion, meaning that it will be given into one of your veins at a controlled rate. The duration of the infusion will be about 1 hour.
This study will be about 65 weeks. It includes a 5-week Screening period, a 48-week Treatment period, and a 12-week Follow?up period.
Subjects will take part in 1 screening visit and 13 dosing visits.
An investigator initiated pilot study of transcutaneous auricular vagal nerve stimulation (taVNS) in mild to moderate Parkinson's disease (PD).
We will assess whether nerve stimulation done on the surface of the skin, (called transcutaneous vagus nerve stimulation (taVNS)) is safe and effective in people with Parkinson's Disease (PD). A small electrical stimulator will be used to deliver electric pulses to a small portion of the left ear of the study participants. Participants will be assigned by chance to either 2 weeks of treatment with real taVNS, or a sham stimulation. The investigator will rate PD motor and cognitive symptoms before, during, and after the 2-week cycle. The investigators will also perform a number of blood and eye movement tests to check for the effectiveness of the stimulation, and perform regular safety checks.
The purpose of this study is to determine if a drug called Nilotinib is safe, if it can be tolerated by patients with PD and to learn if Nilotinib has the possibility of effectively treating PD symptoms. Nilotinib has been approved by the Food and Drug Administration (FDA) to treat certain types of cancer (leukemia) but is considered investigational in this study because it has not been approved for treating PD.
In this study, we are comparing two doses (150mg or 300mg) of Nilotinib to placebo (a pill that looks like the study drug but does not have any active medication in it, like a sugar pill). If you are eligible and choose to be in the study you will be randomly assigned to one of three groups, either:
? 150mg Nilotinib
? 300mg Nilotinib
All three groups will take two pills of the assigned type each day by mouth. ?Randomly' means that the group you are placed in is determined by chance (like tossing a coin). You will have a 2:1 chance of receiving Nilotinib. Neither you nor the researchers will know whether you are taking Nilotinib or placebo.
About 100 individuals will be interviewed and assessed, and 75 people will be asked to participate in this study at 25 clinics across the United States. Approximately 6 participants will be asked to participate in the study at MUSC.
This study will examine changes in brain architecture that are associated with vascular parkinsonism, in comparison to Parkinson's disease. We will do this by using advanced imaging techniques to compare brain structure between subjects with vascular parkinsonism and Parkinson's disease.